These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27147553)

  • 1. Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.
    Ramot Y; Rotkopf S; Gabai RM; Zorde Khvalevsky E; Muravnik S; Marzoli GA; Domb AJ; Shemi A; Nyska A
    Toxicol Pathol; 2016 Aug; 44(6):856-65. PubMed ID: 27147553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
    Golan T; Khvalevsky EZ; Hubert A; Gabai RM; Hen N; Segal A; Domb A; Harari G; David EB; Raskin S; Goldes Y; Goldin E; Eliakim R; Lahav M; Kopleman Y; Dancour A; Shemi A; Galun E
    Oncotarget; 2015 Sep; 6(27):24560-70. PubMed ID: 26009994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
    Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
    Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors.
    Chio II; Yordanov G; Tuveson D
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25430851
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonviral siRNA delivery systems for pancreatic cancer therapy.
    Aghamiri S; Raee P; Talaei S; Mohammadi-Yeganeh S; Bayat S; Rezaee D; Ghavidel AA; Teymouri A; Roshanzamiri S; Farhadi S; Ghanbarian H
    Biotechnol Bioeng; 2021 Oct; 118(10):3669-3690. PubMed ID: 34170520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering polymeric microparticles as theranostic carriers for selective delivery and cancer therapy.
    Win KY; Ye E; Teng CP; Jiang S; Han MY
    Adv Healthc Mater; 2013 Dec; 2(12):1571-5. PubMed ID: 23712912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
    Verma RK; Yu W; Shrivastava A; Shankar S; Srivastava RK
    Sci Rep; 2016 Sep; 6():32743. PubMed ID: 27624879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.
    Titze-de-Almeida R; David C; Titze-de-Almeida SS
    Pharm Res; 2017 Jul; 34(7):1339-1363. PubMed ID: 28389707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multistep, effective drug distribution within solid tumors.
    Shemi A; Khvalevsky EZ; Gabai RM; Domb A; Barenholz Y
    Oncotarget; 2015 Nov; 6(37):39564-77. PubMed ID: 26416413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
    Samore WR; Gondi CS
    Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.